• Allotrope Medical

  Participated · Series A · Jun 2021

  Allotrope Medical develops StimSite™, an FDA-cleared smooth muscle stimulation device that leverages surgeons’ existing laparoscopic and robotic instruments to identify and locate the ureter during pelvic operations. The company is led by founder and CEO Albert Huang, MD, and is based in Houston, TX. StimSite™ is positioned as an intraoperative tool to reduce ureteral injury risk by improving ureter visualization. Allotrope Medical intends to use newly raised funds to accelerate its commercialization plans. The company closed a $4M Series A financing to support those efforts. No operating metrics were disclosed in the article. Allotrope Medical is a Houston-based medical device company developing an innovative surgical device intended to identify ureters and decrease the rate of injury during surgery. The company is led by Founder and CEO Albert Huang MD and is advancing the device through continued development funded by a recent financing. The round was led by Houston Health Ventures with syndication support from the Houston Angel Network; the amount raised was undisclosed. In conjunction with the financing, David Franklin, Managing Director of HHV, will join the Board of Directors alongside Donald Gonzales MD (Founder/CMO, Spirox Inc.) and Mira Sahney (former SVP and GM, Gynecology and ENT Divisions, Smith & Nephew). Allotrope said it will use the funds to continue device development and is targeting commercial availability in late 2018. No operating metrics or prior funding details were disclosed in the article.

No current team members are available.